Morbidity of Chemotherapy Administration and Satisfaction in Breast Cancer Patients: A Comparative Study of Totally Implantable Venous Access Device (TIVAD) Versus Peripheral Venous Access Usage

Singh, Kul Ranjan; Agarwal, Gaurav; Nanda, Gitika; Chand, Gyan; Mishra, Anjali; Agarwal, Amit; Verma, Ashok Kumar; Mishra, Saroj Kanta; Goyal, Prashant

doi:10.1007/s00268-013-2378-x

Cited by 27 publications

(18 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…To our knowledge, patients perceive as a benefit that their arms are left free for activities of daily living while no having more peripheral venipunctures, but they dislike the visibility of ports and site soreness [20]. Overall, patients are satisfied with TIAP [21] and would recommend it [22]. Patients with TIAP, compared to patients with CVC, reported less restriction in daily activities and spent less time thinking that they had a CVAD [23].…”

Section: Introductionmentioning

confidence: 87%

Improving cancer patients’ knowledge about totally implantable access port: a randomized controlled trial

Piredda

Biagioli

Giannarelli³

et al. 2015

Support Care Cancer

View full text Add to dashboard Cite

The interventions provided resulted effective in decreasing patients' physiological indicators of anxiety immediately after TIAP implantation and improving patients' knowledge about TIAP immediately and at 3 months. Adding answers to clarification questions to the booklet was not more effective than the booklet alone. A well-designed booklet with attention both to scientific content and to communication techniques is useful in improving patients' knowledge about TIAP and reducing anxiety.

show abstract

Section: Introductionmentioning

confidence: 87%

Improving cancer patients’ knowledge about totally implantable access port: a randomized controlled trial

Piredda

Biagioli

Giannarelli³

et al. 2015

Support Care Cancer

View full text Add to dashboard Cite

show abstract

“…Totally implantable venous access ports (TIVAPs) can be used for the infusion of various chemotherapeutic drugs [1]. Compared with peripherally inserted central catheters (PICCs), TIVAPs are widely used in the clinic because of their advantages of more convenient care and lower rate of complications [2]. Currently, the application of TIVAPs through either the internal jugular vein (IJV) or subclavian vein (SCV) or cephalic vein surgical cutdown approach is the most widely used [3, 4].…”

Section: Introductionmentioning

confidence: 99%

Ultrasound-guided totally implantable venous access ports via the right innominate vein: a new approach for patients with breast cancer

Qin

Zheng

et al. 2019

World J Surg Onc

View full text Add to dashboard Cite

BackgroundTo evaluate the feasibility and safety of ultrasound-guided totally implantable venous access port (TIVAP) implantation via the right innominate vein in patients with breast cancer.MethodsSixty-seven breast cancer patients underwent ultrasound-guided implantation of TIVAPs via the right innominate vein for administration of chemotherapy. Clinical data including technical success, success rate for the first attempt, periprocedural, and postoperative complications were recorded and retrospectively studied.ResultsAll patients underwent successful surgery. The success rate of the first attempt was 95.52% (64/67). The operation time was 28 to 45 min, with an average of 36 ± 6 min. Periprocedural complications included artery punctures in 1 (1.50%, 1/67) patient. Prior to this study, the mean TIVAP time was 257 ± 3 days (range 41 to 705 days). The rate of postoperative complications was 4.48% (3/67), including catheter-related infections in 1 case and fibrin sheath formation in 2 cases. Up to the present study, three people had unplanned port withdrawal due to complications, and the TIVAPs for 25 patients were still in normal use.ConclusionsThe success rate of ultrasound-guided TIVAPs via the right innominate vein is high with low complications, thus safe and feasible. This technique can provide a new option for chemotherapy of breast cancer patients.

show abstract

“…The association of age with late complications is likely attributable to age-related vascular changes and to the relatively poor general health situation. [ 23 , 24 ] Patients with breast cancer, lung cancer, and gastric cancer had a higher rate of complication. This is likely attributable to the higher rate of indwelling TIVAP in patients with these cancer types as compared with that in patients with other cancers in our hospital.…”

Section: Discussionmentioning

confidence: 99%

Late complications of totally implantable venous access ports in patients with cancer

et al. 2018

Medicine

View full text Add to dashboard Cite

The aim of this study was to assess the incidence rate and the risk factors for late complications associated with use of central totally implanted venous access devices (TIVAPs) in patients with cancer, and to devise nursing strategies to minimize late complications.This retrospective study included 500 patients with TIVAPs from 2012 to 2015. Multivariable logistic regression analysis was performed to assess the effect of sex, age, primary diagnosis, duration of surgery, and the length of hospital stay on the incidence of late complications of TIVAP.The cumulative maintenance period of TIVAP was 159,605 days. Late complications included catheter-related obstruction (n = 14; 2.8%), infection (n = 3; 0.6%), drug extravasation (n = 1; 0.2%), and catheter exposure (n = 1; 0.2%). Multivariate analyses revealed that age, breast cancer, lung cancer, and gastric cancer were risk factors for the late complications associated with TIVAP.There was a low incidence of late complications with TIVAP use. Catheter-related obstruction is the most frequent late complication of TIVAP. Risk factors for TIVAP-associated late complications include age and certain cancers, such as breast cancer, lung cancer, and gastric cancer.

show abstract

Morbidity of Chemotherapy Administration and Satisfaction in Breast Cancer Patients: A Comparative Study of Totally Implantable Venous Access Device (TIVAD) Versus Peripheral Venous Access Usage

Abstract: Breast cancer chemotherapy via TIVAD is safe and convenient and results in high satisfaction levels, although it involves additional expenditure. Chemotherapy via PIVA is acceptable, albeit with lower satisfaction, more so in those receiving more than six chemotherapy cycles.

Cited by 27 publications

References 24 publications

Improving cancer patients’ knowledge about totally implantable access port: a randomized controlled trial

Improving cancer patients’ knowledge about totally implantable access port: a randomized controlled trial

Ultrasound-guided totally implantable venous access ports via the right innominate vein: a new approach for patients with breast cancer

Late complications of totally implantable venous access ports in patients with cancer

Contact Info

Product

Resources

About